Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT

Founder-led company

Phathom Pharmaceuticals stock price today

$10.55
+2.37
+28.97%
Financial Health
0
1
2
3
4
5
6
7
8
9

Phathom Pharmaceuticals stock price monthly change

-29.79%
month

Phathom Pharmaceuticals stock price quarterly change

-29.79%
quarter

Phathom Pharmaceuticals stock price yearly change

-11.66%
year

Phathom Pharmaceuticals key metrics

Market Cap
490.26M
Enterprise value
281.67M
P/E
-1.54
EV/Sales
N/A
EV/EBITDA
-1.65
Price/Sales
N/A
Price/Book
-4.54
PEG ratio
0.05
EPS
-4.40
Revenue
N/A
EBITDA
-202.98M
Income
-246.63M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Phathom Pharmaceuticals stock price history

Phathom Pharmaceuticals stock forecast

Phathom Pharmaceuticals financial statements

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Profit margin
Jun 2023 0 -40.96M
Sep 2023 0 -43.24M
Dec 2023 682K -79.57M -11667.16%
Mar 2024 1.91M -82.85M -4333.26%
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Analyst Estimates
Mar 2024 1.91M -82.85M -4333.26%
Sep 2025 49.8M -42.39M -85.14%
Oct 2025 49.8M -46.11M -92.6%
Dec 2025 59.3M -38.52M -64.97%
  • Analysts Price target

  • Financials & Ratios estimates

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Debt to assets
Jun 2023 265039000 247.43M 93.36%
Sep 2023 236992000 254.76M 107.5%
Dec 2023 413842000 486.60M 117.58%
Mar 2024 356499000 505.00M 141.66%
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Cash Flow
Jun 2023 -22.2M -6K 141.50M
Sep 2023 -31.91M -939K 13K
Dec 2023 -43.79M -475K 211.99M
Mar 2024 -69.02M -40K 9.9M

Phathom Pharmaceuticals alternative data

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Employee count
Aug 2023 112
Sep 2023 112
Oct 2023 112
Nov 2023 112
Dec 2023 112
Jan 2024 112
Feb 2024 112
Mar 2024 452
Apr 2024 452
May 2024 452
Jun 2024 452
Jul 2024 452

Phathom Pharmaceuticals other data

31.94% -41.14%
of PHAT is owned by hedge funds
12.49M -15.87M
shares is hold by hedge funds

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insider trades (number of shares)
Period Buy Sel
Jul 2024 0 49074
Dec 2024 22500 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
KARBE FRANK director
Common Stock 12,500 $7.93 $99,088
Purchase
PARIKH ASIT director
Common Stock 10,000 $8.13 $81,250
Sale
NABULSI AZMI officer: Chief Op.. Common Stock 10,901 $11.72 $127,760
Sale
HENDERSON MOLLY officer: CFO and CBO
Common Stock 4,325 $11.72 $50,689
Sale
CURRAN TERRIE director, officer.. Common Stock 33,848 $11.72 $396,699
Sale
HENDERSON MOLLY officer: CFO and CBO
Common Stock 811 $7.8 $6,326
Sale
HENDERSON MOLLY officer: CFO and CBO
Common Stock 11,681 $8.95 $104,545
Sale
HENDERSON MOLLY officer: CFO and CBO
Common Stock 1,960 $11.41 $22,368
Sale
HENDERSON MOLLY officer: CFO and CBO
Common Stock 2,110 $12.87 $27,164
Purchase
NABULSI AZMI officer: Chief Op.. Common Stock 10,000 $8.26 $82,600
Wednesday, 11 December 2024
globenewswire.com
Friday, 6 December 2024
zacks.com
Tuesday, 19 November 2024
zacks.com
Sunday, 10 November 2024
seekingalpha.com
Thursday, 7 November 2024
zacks.com
Monday, 4 November 2024
globenewswire.com
Monday, 28 October 2024
globenewswire.com
Sunday, 27 October 2024
globenewswire.com
Wednesday, 25 September 2024
prnewswire.com
Thursday, 29 August 2024
globenewswire.com
Monday, 19 August 2024
globenewswire.com
Saturday, 10 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
globenewswire.com
Thursday, 18 July 2024
globenewswire.com
Wednesday, 26 June 2024
seekingalpha.com
Friday, 7 June 2024
investorplace.com
Tuesday, 28 May 2024
globenewswire.com
Saturday, 11 May 2024
Seeking Alpha
Thursday, 9 May 2024
Zacks Investment Research
Monday, 18 March 2024
Seeking Alpha
Thursday, 7 March 2024
Seeking Alpha
Wednesday, 31 January 2024
GlobeNewsWire
Monday, 1 January 2024
Seeking Alpha
Wednesday, 25 October 2023
GlobeNewsWire
Thursday, 5 October 2023
Seeking Alpha
Tuesday, 5 September 2023
GlobeNewsWire
Monday, 7 August 2023
InvestorPlace
Friday, 14 July 2023
Seeking Alpha
Friday, 7 July 2023
Zacks Investment Research
  • What's the price of Phathom Pharmaceuticals stock today?

    One share of Phathom Pharmaceuticals stock can currently be purchased for approximately $10.55.

  • When is Phathom Pharmaceuticals's next earnings date?

    Unfortunately, Phathom Pharmaceuticals's (PHAT) next earnings date is currently unknown.

  • Does Phathom Pharmaceuticals pay dividends?

    No, Phathom Pharmaceuticals does not pay dividends.

  • How much money does Phathom Pharmaceuticals make?

    Phathom Pharmaceuticals has a market capitalization of 490.26M.

  • What is Phathom Pharmaceuticals's stock symbol?

    Phathom Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PHAT".

  • What is Phathom Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Phathom Pharmaceuticals?

    Shares of Phathom Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Phathom Pharmaceuticals's key executives?

    Phathom Pharmaceuticals's management team includes the following people:

    • Ms. Terrie J. Curran Pres, Chief Executive Officer & Director(age: 56, pay: $865,850)
    • Dr. Azmi Nabulsi M.D., M.P.H. Co-Founder & Chief Operating Officer(age: 66, pay: $727,970)
    • Mr. David A. Socks Co-Founder & Director(age: 51, pay: $477,490)
  • Is Phathom Pharmaceuticals founder-led company?

    Yes, Phathom Pharmaceuticals is a company led by its founders Dr. Azmi Nabulsi M.D., M.P.H. and Mr. David A. Socks.

  • How many employees does Phathom Pharmaceuticals have?

    As Jul 2024, Phathom Pharmaceuticals employs 452 workers.

  • When Phathom Pharmaceuticals went public?

    Phathom Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.

  • What is Phathom Pharmaceuticals's official website?

    The official website for Phathom Pharmaceuticals is phathompharma.com.

  • Where are Phathom Pharmaceuticals's headquarters?

    Phathom Pharmaceuticals is headquartered at 100 Campus Drive, Florham Park, NJ.

  • How can i contact Phathom Pharmaceuticals?

    Phathom Pharmaceuticals's mailing address is 100 Campus Drive, Florham Park, NJ and company can be reached via phone at 877 742 8466.

Phathom Pharmaceuticals company profile:

Phathom Pharmaceuticals, Inc.

phathompharma.com
Exchange:

NASDAQ

Full time employees:

452

Industry:

Biotechnology

Sector:

Healthcare

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

100 Campus Drive
Florham Park, NJ 07932

CIK: 0001783183
ISIN: US71722W1071
CUSIP: 71722W107